BARDA is providing funding, technical assistance and expertise to support the development of a combination diagnostic test for influenza A/B and COVID-19.Full Announcement
MedicalCountermeasures.gov can help you keep up-to-date on the latest developments in federal medical countermeasures activities, with information on public meetings and conferences, procurement and grant opportunities, strategies, reports, federal guidance on the development of medical countermeasures, and other announcements.
Provides links to information about public meetings, both upcoming and past, on issues pertaining to public health threats, both naturally occurring and manmade. Also included are links to online Meeting Libraries, such as the NIH Videocasting site.Learn More
Procurements and Grants
Provides links to relevant federal guidance on issues related to the development medical countermeasures, including information on Emergency Use Authorization, the Animal Efficacy Rule, and the Select Agent Rule.
Federal Business Opportunities (FedBizOpps) is the single government point-of-entry (GPE) for Federal government procurement opportunities over $25,000. Commercial vendors seeking Federal markets for their products and services can search, monitor and retrieve opportunities solicited by the entire Federal contracting community through FedBizOpps.Learn More
Provides links to relevant federal guidance on issues related to the development medical countermeasures, including information on Emergency Use Authorization, the Animal Efficacy Rule, and the Select Agent Rule.Learn More
Strategies and Reports
Provides links to sources of information useful to those involved in the research, development, and acquisition of medical countermeasures products, including Project Bioshield, and Public Health Emergency Medical Countermeasures Enterprise.Learn More
The Federal Government has launched several major initiatives intended to accelerate basic research and development of vaccines, therapeutics, and diagnostics for naturally occurring and manmade threats.Learn More
Latest announcements related to medical countermeasures
OPPORTUNITIES TO PARTNER WITH BARDA
BARDA collaborated with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army Contracting Command to modify an existing agreement with Eli Lilly and Company to increase the number of treatment courses of the investigational monoclonal antibody therapeutic, bamlanivimab, the federal government can purchase for use in treating non-hospitalized COVID-19 patients.Full Announcement
The Department of Health and Human Services (HHS) and the Department of Defense (DOD) today announced the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic, a combination of casirivimab and imdevimab, to be delivered in the first half of 2021 to treat non-hospitalized, high-risk COVID-19 patients.Full Announcement